SALT LAKE CITY, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed an ...
On Thursday, Exscientia plc (NASDAQ:EXAI) agreed to merge with Recursion Pharmaceuticals Inc. (NASDAQ:RXRX). Exscientia shareholders will receive 0.7729 Recursion shares for each Exscientia share, ...
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback